More stories

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to...

With the addition of psilocybin and MDMA to Health Canada’s Special Access Program, Mydecine looks to offer a package of cGMP products and support...

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND’s Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /CNW/ – MYND Life Sciences Inc....

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess...

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat...

TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development...

Wesana Health Provides Strategic and Operational Updates

Wesana granted pre-IND meeting with FDA, currently set for March 11, 2022 Wesana Clinics exhibited a record quarter of billings, new patient visits, telemedicine...

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate),...

The Allowed Claims include Composition of FT-104, which is a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT TORONTO, Jan. 11, 2022...

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the...

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to...

-Enrollment expected to begin in early 2022 – TORONTO–( BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on...

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment...

Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events Toronto, Ontario–(Newsfile Corp. – January 11,...

PT283 – Greg McKee – Nociplastic Pain and Psychedelics

In this episode of the podcast, Joe interviews Greg McKee: Chairman and CEO of Tryp Therapeutics, an early-stage biotech company focusing on nociplastic pain...

Psychedelic Research and Clinical Trials in 2021

Part of our Psychedelics 2021: A Year in Review Series See the full series The resurgence of research into psychedelics has continued to thrive...

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening...

The new serotonin receptor model (5-HT 2A) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules....

Most popular